Clarus Therapeutics Inc., of Northbrook, Ill., withdrew its filing for an initial public offering, stating that the terms currently obtainable in the public marketplace are not sufficiently attractive. The specialty pharma firm had previously hoped to sell 5 million shares for $11 to $13 apiece.